Hu Guang-Sheng, Li Ying-Qing, Yang Yu-Ming, Shi Wei, Liao Ai-Jun, Yao Yu-Hong, Zeng Bin, Yuan Jie
Department of Gastroenterology, The First Affiliated Hospital, NanHua University, 69 ChuanShan Road, Hengyang, 421001, People's Republic of China,
Tumour Biol. 2014 Sep;35(9):8625-32. doi: 10.1007/s13277-014-2105-8. Epub 2014 May 28.
Golgi phosphoprotein 3 (GOLPH3) is recently demonstrated to function as an oncogene involved in the development and progression of cancers. However, little is known about GOLPH3 expression and its clinical significance in hepatocellular carcinoma (HCC). The levels of GOLPH3 messenger RNA (mRNA) and protein in HCC cell lines and fresh tissues were determined by quantitative RT-PCR and western blotting. Additionally, the protein expression of GOLPH3 was detected in 167 paraffin-embedded HCC samples by immunohistochemistry. GOLPH3 mRNA and protein was overexpressed in HCC cell lines and tissues than the immortalized normal hepatocyte cell line LO2 and the adjacent nontumorous live tissues, respectively. High GOLPH3 expression was positively correlated with high serum AFP level (P = 0.015) and more tumor recurrence or metastasis (P = 0.010). In addition, HCC patients with high GOLPH3 expression had poorer overall survival (hazard ratio (HR), 1.87; 95 % confidence interval (CI), 1.19-2.94; P = 0.006) and poorer disease-free survival (HR, 1.90; 95 % CI, 1.21-2.98; P = 0.005) than those with low GOLPH3 expression. The cumulative 5-year survival rate was only 35.19 % (95 % CI, 26.18-44.20 %) in the high GOLPH3 expression group, whereas it was 55.93 % (95 % CI, 43.26-68.60 %) in the low GOLPH3 expression group. Furthermore, multivariate Cox regression analysis demonstrated that the expression of GOLPH3, tumor size, and tumor multiplicity were independent prognostic predictors for HCC patients. GOLPH3 was overexpressed in HCC at both the mRNA and protein levels, and high expression of GOLPH3 could be served as a novel and potential prognostic biomarker for HCC patients.
高尔基体磷蛋白3（GOLPH3）最近被证明是一种癌基因，参与癌症的发生和发展。然而，关于GOLPH3在肝细胞癌（HCC）中的表达及其临床意义知之甚少。通过定量逆转录PCR和蛋白质印迹法测定HCC细胞系和新鲜组织中GOLPH3信使核糖核酸（mRNA）和蛋白质的水平。此外，通过免疫组织化学检测167例石蜡包埋的HCC样本中GOLPH3的蛋白表达。与永生化正常肝细胞系LO2和相邻非肿瘤肝组织相比，GOLPH3 mRNA和蛋白质分别在HCC细胞系和组织中过表达。高GOLPH3表达与高血清甲胎蛋白水平（P = 0.015）以及更多的肿瘤复发或转移（P = 0.010）呈正相关。此外，与低GOLPH3表达的HCC患者相比，高GOLPH3表达的HCC患者总生存期较差（风险比（HR），1.87；95%置信区间（CI），1.19 - 2.94；P = 0.006），无病生存期也较差（HR，1.90；95%CI，1.21 - 2.98；P = 0.005）。高GOLPH3表达组的累积5年生存率仅为35.19%（95%CI，26.18 - 44.20%），而低GOLPH3表达组为55.93%（95%CI，43.26 - 68.60%）。此外，多因素Cox回归分析表明，GOLPH3的表达、肿瘤大小和肿瘤数量是HCC患者独立的预后预测指标。GOLPH3在HCC的mRNA和蛋白水平均过表达，高表达的GOLPH3可作为HCC患者一种新的潜在预后生物标志物。
